Primary aldosteronism : Pathophysiological mechanisms of cell death and proliferation
Copyright © 2022 Tetti, Gong, Veglio, Reincke and Williams..
Primary aldosteronism is the most common surgically curable form of hypertension. The sporadic forms of the disorder are usually caused by aldosterone overproduction from a unilateral adrenocortical aldosterone-producing adenoma or from bilateral adrenocortical hyperplasia. The main knowledge-advances in disease pathophysiology focus on pathogenic germline and somatic variants that drive the excess aldosterone production. Less clear are the molecular and cellular mechanisms that lead to an increased mass of the adrenal cortex. However, the combined application of transcriptomics, metabolomics, and epigenetics has achieved substantial insight into these processes and uncovered the evolving complexity of disrupted cell growth mechanisms in primary aldosteronism. In this review, we summarize and discuss recent progress in our understanding of mechanisms of cell death, and proliferation in the pathophysiology of primary aldosteronism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 13(2022) vom: 02., Seite 934326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tetti, Martina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4964P6T9RB |
|---|
| Anmerkungen: |
Date Completed 26.08.2022 Date Revised 26.08.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2022.934326 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345227867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345227867 | ||
| 003 | DE-627 | ||
| 005 | 20231226024603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2022.934326 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345227867 | ||
| 035 | |a (NLM)36004349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tetti, Martina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary aldosteronism |b Pathophysiological mechanisms of cell death and proliferation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2022 | ||
| 500 | |a Date Revised 26.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Tetti, Gong, Veglio, Reincke and Williams. | ||
| 520 | |a Primary aldosteronism is the most common surgically curable form of hypertension. The sporadic forms of the disorder are usually caused by aldosterone overproduction from a unilateral adrenocortical aldosterone-producing adenoma or from bilateral adrenocortical hyperplasia. The main knowledge-advances in disease pathophysiology focus on pathogenic germline and somatic variants that drive the excess aldosterone production. Less clear are the molecular and cellular mechanisms that lead to an increased mass of the adrenal cortex. However, the combined application of transcriptomics, metabolomics, and epigenetics has achieved substantial insight into these processes and uncovered the evolving complexity of disrupted cell growth mechanisms in primary aldosteronism. In this review, we summarize and discuss recent progress in our understanding of mechanisms of cell death, and proliferation in the pathophysiology of primary aldosteronism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adrenal adenoma | |
| 650 | 4 | |a adrenal gland | |
| 650 | 4 | |a aldosterone | |
| 650 | 4 | |a cell death | |
| 650 | 4 | |a endocrine hypertension | |
| 650 | 4 | |a ferroptosis | |
| 650 | 4 | |a hyperaldosteronism | |
| 650 | 4 | |a proliferation | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 700 | 1 | |a Gong, Siyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Veglio, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Reincke, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Tracy Ann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 13(2022) vom: 02., Seite 934326 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:02 |g pages:934326 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2022.934326 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 02 |h 934326 | ||